These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38385206)

  • 1. Responsiveness to pembrolizumab in severe early-onset natalizumab associated PML-IRIS in patient with relapsing-remitting multiple sclerosis.
    Ercan MB; Kocer B; Altiparmak T; Arslan I
    Mult Scler; 2024 May; 30(6):760-762. PubMed ID: 38385206
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
    Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
    Marousi S; Travasarou M; Karageorgiou CE; Gheuens S; Koralnik IJ
    Neurology; 2012 Nov; 79(21):2160; author reply 2160. PubMed ID: 23170016
    [No Abstract]   [Full Text] [Related]  

  • 4. Global Hyperperfusion in the Brain at Onset of the Immune Reconstitution Inflammatory Syndrome in a Patient With Natalizumab-Associated PML.
    Yokote H; Mori K; Nakamichi K; Matsuda T; Miura Y
    Neurology; 2024 Oct; 103(7):e209874. PubMed ID: 39213467
    [No Abstract]   [Full Text] [Related]  

  • 5. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab.
    Toorop AA; van Lierop ZYG; Strijbis EEM; Teunissen CE; Petzold A; Wattjes MP; Barkhof F; de Jong BA; van Kempen ZLE; Killestein J
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33051344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.
    Gheuens S; Smith DR; Wang X; Alsop DC; Lenkinski RE; Koralnik IJ
    Neurology; 2012 May; 78(18):1390-3. PubMed ID: 22517104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?
    Wattjes MP; Verhoeff L; Zentjens W; Killestein J; van Munster ET; Barkhof F; van Eijk JJ
    J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1176-7. PubMed ID: 23695498
    [No Abstract]   [Full Text] [Related]  

  • 8. Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report.
    Puig-Casadevall M; Álvarez-Bravo G; Varela AQ; Robles-Cedeño R; Sànchez Cirera L; Miguela A; Laguillo G; Montalban X; Hauser SL; Ramió-Torrentà L
    Eur J Neurol; 2023 Oct; 30(10):3357-3361. PubMed ID: 37485841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of FDG-PET imaging in distinguishing PML-IRIS from PML in a patient treated with natalizumab.
    Baheerathan A; McNamara C; Kalam S; Rane N; Barwick TD; Grote H; Nicholas R
    Neurology; 2018 Sep; 91(12):572-573. PubMed ID: 30224501
    [No Abstract]   [Full Text] [Related]  

  • 10. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
    Kleinschmidt-DeMasters BK; Miravalle A; Schowinsky J; Corboy J; Vollmer T
    J Neuropathol Exp Neurol; 2012 Jul; 71(7):604-17. PubMed ID: 22710964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment.
    Fabis-Pedrini MJ; Xu W; Burton J; Carroll WM; Kermode AG
    J Clin Neurosci; 2016 Mar; 25():145-7. PubMed ID: 26541323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal supportive treatment in natalizumab-related PML in a MS patient.
    Lalive PH; Bridel C; Ferfoglia RI; Kaiser L; Du Pasquier R; Barkhof F; Haller S
    J Neurol Neurosurg Psychiatry; 2015 Mar; 86(3):354-5. PubMed ID: 24957322
    [No Abstract]   [Full Text] [Related]  

  • 13. [A case of subtentorial progressive multifocal leucoencephalopathy in a patient treated with natalizumab].
    Simaniv TO; Ivanova MV; Bryukhov VV; Zakharova MN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2. Vyp. 2):98-106. PubMed ID: 31156248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deaths and disability from natalizumab are no longer tolerable: Commentary.
    Hutchinson M
    Mult Scler; 2012 Aug; 18(8):1073. PubMed ID: 22807472
    [No Abstract]   [Full Text] [Related]  

  • 15. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.
    Metz I; Radue EW; Oterino A; Kümpfel T; Wiendl H; Schippling S; Kuhle J; Sahraian MA; Gray F; Jakl V; Häusler D; Brück W
    Acta Neuropathol; 2012 Feb; 123(2):235-45. PubMed ID: 22057786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
    Damasceno A; von Glehn F; Martinez AR; Longhini AL; Deus-Silva L; Brandão CO; Santos LM; Damasceno BP
    Mult Scler; 2011 Nov; 17(11):1397-8. PubMed ID: 21900356
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
    Rath L; Vijiaratnam N; Skibina O
    Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transient punctuate enhancing lesions preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Taieb G; Renard D; Thouvenot E; Servillo G; Castelnovo G
    J Neurol Sci; 2014 Nov; 346(1-2):364-5. PubMed ID: 25241939
    [No Abstract]   [Full Text] [Related]  

  • 19. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
    Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab.
    Blinkenberg M; Sellebjerg F; Leffers AM; Madsen CG; Sørensen PS
    Mult Scler; 2013 Aug; 19(9):1226-9. PubMed ID: 23508652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.